I am a
Home I AM A Search Login

Papers of the Week

Papers: 15 Jun 2024 - 21 Jun 2024

2024 Jun 13

J Neurol


Implications of therapy interruption on monthly migraine days and modified migraine disability assessment in patients treated with erenumab for chronic and episodic migraine: SQUARE study interim results.


Gantenbein AR, Bonvin C, Kamm CP, Schankin CJ, Zecca C, Zieglgänsberger D, Merki-Feld GS, Pohl H, Rudolph N, Ryvlin P, Agosti R, Schäfer E, Meyer I, Kulartz-Schank M, Arzt ME


There are limited real-world data in Switzerland examining the impact of erenumab, a fully human IgG2 monoclonal antibody targeting the calcitonin gene-related peptide (CGRP) receptor, on migraine-related quality of life.